Table 3.

Focal Therapy Cancer Control and Complication Rates

Study	Type	N	Mean F/U	bDFS % (Criteria)	Negative Biopsy	Potency	Continence
			(mo)		(%)	Preserved	Preserved
						(%)	(%)
Bahn et al16	Cryo	31	70	92.9 (ASTRO)	96	88.9	100
Lambert et al17	Cryo	25	28	88 (PSA nadir)	96	70.8	100
					Untreated lobe:
					2 positive bx
Ellis et al18	Cryo	60	15.2	80.4 (ASTRO)	98.3	70.6	96.3
					Untreated lobe:
					13 positive bx
Onik et al19	Cryo	54	54	100 (ASTRO)	97.9	90	100
Muto et al20	HIFU	29	32	83.3 — low risk	76.5	NR	100
				53.6 — moderate risk
				(3 consecutive PSA
				increases)
El Fegoun et al21	HIFU	12	37	90 at 5 years	91	100	100
				38 at 10 years
				(recurrence-free survival)
Ahmed et al22	HIFU	20	36.7	89.5 (absence of cancer)	88.9	95	95

ASTRO, American Society for Therapeutic Radiology and Oncology; bDFS, biochemical disease-free survival; bx, biopsy; Cryo, focal cryoablation; F/U, follow-up; HIFU, high-intensity focused ultrasound; N, number of patients; PSA, prostate specific antigen.